Here's how Novo's triple G weight loss drug (UBT251) compares to Eli Lilly's (Retatrutide) at the same 24 week timepoint (Just phase 2, different populations, no safety data for UBT251) Triple agonist UBT251 delivers up to 19.7% mean weight loss after 24 weeks in phase 2 trial in China
Physical Examination On presentation, the patient was conscious, alert, and oriented, and hemodynamically stable, with a temperature of 37.1 C, heart rate of 82 bpm, blood pressure of 126/72 mmHg, respiratory rate of 17 breaths/min, and oxygen saturation of 97% on room air
AOX Ferulic Glutathione Serum's plant extracts strengthen the skin's lipid barrier, locking in moisture and making it more resilient to environmental irritation
Chanmee T, Ontong P, Itano N